Supernus (SUPN) director Carrolee Barlow granted 4,475 common shares

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. director Carrolee Barlow reported routine equity award activity. On February 24, 2026, 4,475 restricted stock units were disposed of back to the company as they converted into 4,475 shares of common stock at no cash cost. After this grant/award acquisition, Barlow directly owns 27,045 shares of Supernus common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Barlow Carrolee

Role Director

Type	Security	Shares	Price	Value
Disposition	Restricted Stock Unit	4,475	$0.00	--
Grant/Award	Common Stock	4,475	$0.00	--

Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct); Common Stock — 27,045 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Barlow Carrolee

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		A		4,475	A	$0	27,045	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/24/2026		D			4,475	(2)	(2)	Common Stock	4,475	$0	0	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

2. These restricted stock units will be settled in common stock upon vesting, which will occur on February 19, 2026.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Supernus (SUPN) director Carrolee Barlow report on this Form 4?

Carrolee Barlow reported a routine equity award transaction involving Supernus shares. 4,475 restricted stock units were converted and disposed to the issuer, and she received 4,475 common shares, bringing her direct ownership to 27,045 Supernus shares following the transaction on February 24, 2026.

How many Supernus (SUPN) shares did Carrolee Barlow acquire in this filing?

Carrolee Barlow acquired 4,475 shares of Supernus common stock through a grant or award. These shares came from the settlement of restricted stock units, with no cash price per share, and increased her direct holdings to a total of 27,045 common shares after the transaction.

What happened to the restricted stock units reported by Supernus (SUPN) director Carrolee Barlow?

4,475 restricted stock units were reported as disposed of to the issuer when they converted into common stock. Each unit represented the right to receive one Supernus share upon vesting, and settlement in common stock occurs upon vesting as described in the accompanying footnotes.

What is Carrolee Barlow’s Supernus (SUPN) share ownership after this Form 4?

After the reported transactions, Carrolee Barlow directly owns 27,045 shares of Supernus common stock. This figure reflects the 4,475 common shares she received from the equity award, following the disposition of an equal number of restricted stock units back to the issuer.

Were the Supernus (SUPN) shares in this Form 4 bought or granted?

The Supernus shares were granted as an award, not bought on the market. The filing classifies the 4,475 common shares as a grant, award, or other acquisition at a price per share of $0.00, arising from the settlement of restricted stock units upon vesting.